OVERVIEW

The Joint COMydAL, COLYM, MPNCo&D, and 6th Annual Meeting of the International Academy for Clinical Hematology (IACH) is organized by CME Congresses Ltd and will be held from Oct 05 - 07, 2023 at New Cap Event Center, Paris, Ile-de-France, France.

Description:
The field of hematology continues to make significant progress, even in these challenging times. We have seen fascinating developments, especially in the fields of MDS, AML and ALL, Lymphoma, and MPN.

The joint 2023 IACH Meeting will continue to serve as a unique forum where the most compelling and controversial topics facing clinicians are presented. The program will provide a platform to interact and discuss with leading experts many key and developing issues in clinical hematology and within these specialized fields.

COMydAL Program

Friday, October 6, 2023
 Hall A
 
 MDS-AML-ALL (COMydAL)
09:15-10:45Session 1:
Classification, risk stratification & response assessment updates for MDS
 
 Moderator:
Ana Alfonso Piérola, Spain
09:15-09:30Prognostication updates:
Matteo Della Porta, Italy
09:30-09:45Classification updates:
Leonor Arenillas, Spain
09:45-10:00Response assessment updates:
Amer Zeidan, USA
10:00-10:15Is MRD assessment ready for use in MDS?
Arjan van de Loosdrecht, Netherlands
10:15-10:45Roundtable discussion:
All session faculty
10:45-11:15Coffee Break
11:15-12:45Session 2:
Management of lower risk MDS
 Moderator:
David Valcárcel, Spain
11:15-11:30ESA/Lenalidomide/IST/chelation:
María Díez Campelo, Spain
11:30-11:45What is the role for chelation in MDS?
Eolia Brissot, France
11:45-12:00Imetelstat/TGF-beta/Roxadustat:
Valeria Santini, Italy
12:00-12:15Early phase agent review:
Rami Komrokji, USA
12:15-12:45Roundtable discussion:
All session faculty
12:45-13:15Lunch Box Pick-up and Break
 COMydAL Program Pause
 
14:45-16:15Session 3:
Management of higher risk MDS
 Moderator:
Marie Sébert, France
14:45-15:00Injectable and oral HMAs:
Pierre Fenaux, France
15:00-15:15Novel agents in advanced trials (Magro/Sabato):
Guillermo Sanz, Spain
15:15-15:30IDH inhibitors for MDS:
Lionel Ades, France
15:30-15:45Transplant considerations in MDS:
Ibrahim Yakoub-Agha, France
15:45:16:15Roundtable discussion:
All session faculty
16:15-16:30Coffee Break
16:30-18:00Session 4:
Prognosis, MRD and transplantation for AML
 Moderator:
Agnieszka Wierzbowska, Poland
16:30-16:45How do I use molecular data in clinical care of MDS and AML patients:
Lisa Pleyer, Austria
16:45-17:00What is the role of MRD in AML?
Michael Heuser, Germany
17:00-17:15How should we manage patients with MDS/AML?
Raphael Itzykson, France
17:15-17:30Should we use maintenance therapy post-transplant?
Lars Bullinger, Germany
17:30-18:00Roundtable discussion:
All session faculty
Saturday, October 7, 2023
 Hall A
 
 MDS-AML-ALL (COMydAL)
09:00-10:30Session 5:
Updates in AML management in 2023 – Agents in clinic
 
 Moderator:
Jessica Altman, USA
09:00-09:15What is standard frontline therapy for fit patients in 2023?
Jessica Altman, USA
09:15-09:30What is standard frontline therapy for unfit patients in 2023?
Amer Zeidan, USA
09:30-09:45How do I manage relapsed/refractory AML in 2023?
Andrew Wei, Australia
09:45-10:00Do triplets have a place in current practice of AML?
Gail Roboz, USA
10:00-10:30Roundtable discussion:
All session faculty
10:30-11:00Coffee Break
11:00-12:30Session 6:
Updates in AML management in 2023 – Investigational approaches
 Moderator:
Marion Subklewe, Germany
11:00-12:30Which agents in development have the most promise?
Thomas Cluzeau, France
11:15-11:30Immune investigational approaches (ADCs, Bites, CAR T cells, ICB):
Marion Subklewe, Germany
11:30-11:45Options for patients with TP53 mutant MDS/AML?
Naval Daver, USA
11:45-12:00Updates in mechanisms of resistance in AML and how to overcome them:
Klaus Metzeler, Germany
12:00-12:30Roundtable discussion:
All session faculty
12:30-13:00Lunch Box Pick-up and Break
 COMydAL Program Pause
 
14:45-16:15Session 7:
How do I manage ALL in 2023?
 Moderator:
Elias Jabbour, USA
14:45-15:00Ph -ve ALL:
Robin Foà, Italy
15:00-15:15Ph +ve ALL:
Elias Jabbour, USA
15:15-15:30T-cell ALL:
Nicola Gökbuget, Germany
15:30-15:45Cellular therapy and transplant considerations for ALL:
Sridhar Chaganti, UK
15:45:16:15Roundtable discussion:
All session faculty
16:15-16:30Coffee Break
16:30-17:00IACH Closing Plenary Lecture

COLYM Program

Friday, October 6, 2023
 Hall B
 
 Lymphoma (COLYM)
09:15-10:45Session 1:
What’s new in the field of lymphomas? Keynote lectures
 
 Moderators:
Stefano Luminari, Italy; Anna Sureda, Spain
 Debate: Bringing genomics to the clinic in DLBCL:
09:15-09:35The pathologist point of view:
Miguel Angel Piris, Spain
09:35-09:55The clinician point of view:
Andrew Davies, UK
09:55-10:15Prognostic factors for cellular therapy strategies:
Alberto Mussetti, Spain
10:15-10:45Roundtable discussion:
All session faculty
10:45-11:15Coffee Break
11:15-12:45Session 2:
CLL and Richter’s syndrome
 Moderators:
Mehdi Hamadani, USA; Farrukh Awan, USA
11:15-11:35Front line therapy in CLL: Time limited vs continuous:
Farrukh Awan, USA
11:35-11:55High risk CLL in the era of BTKi and BCL2 inhibitors: Is allo-HCT still a valid option?
Mohamed Kharfan-Dabaja, USA
 Debate: Best therapeutic option of Richter’s syndrome is:
11:55-12:05Novel agents:
Farrukh Awan, USA
12:05-12:15Allo-HCT:
Alex Herrera, USA
12:15-12:25CAR T cells:
Sairah Ahmed, USA
12:25-12:45Roundtable discussion:
All session faculty
12:45-13:15Lunch Box Pick-up and Break
 COLYM Program Pause
 
14:45-16:15Session 3:
Follicular lymphoma
 Moderators:
Mehdi Hamadani, USA; Mohamed Kharfan-Dabaja, USA
 Debate: Best option for treatment naïve FL patients is:
14:45-15:00Chemo free strategies:
Julio Chavez, USA
15:00-15:15R-chemo strategies:
Pau Abrisqueta, Spain
 Debate: Sequencing treatment in RR FL patients:
15:15-15:30Bispecific MoAb before CAR T cells are the SOC:
Alex Herrera, USA
15:30-15:45CAR T cells before bispecific MoAb are the SOC:
Mazyar Shadman, USA
15:45-16:15Roundtable discussion:
All session faculty
16:15-16:30Coffee Break
16:30-18:00Session 4:
Diffuse large B cell lymphomas
 Moderators:
Anna Sureda, Spain; Alex Herrera, USA
 Debate: Is R-CHOP still the SOC for first-line therapy in DLBCL?
16:30-16:45Yes:
Marek Trn?ný, Czech Republic
16:45-17:00No:
Hervé Tilly, France
 Debate: Most feasible option for 3L therapy in DLBCL patients:
17:00-17:15CD19 autologous CAR T cells:
Anna Sureda, Spain
17:15-17:30CD20-CD3 bispecific monoclonal antibodies:
Elly Lugtenburg, Netherlands
17:30-18:00Roundtable discussion:
All session faculty
Saturday, October 7, 2023
 Hall B
 
 Lymphoma (COLYM)
09:00-10:30Session 5:
Peripheral T cell lymphomas 
 
 Moderators:
Mohamed Kharfan-Dabaja, USA; Julio Chavez, USA
09:00-09:15Insights in molecular pathology of PTCL:
Laurence de Leval, Switzerland
 Debate: PTCL NOS in CR1:
09:15-09:30SOC is watchful waiting:
Eva Domingo-Doménech, Spain
09:30-09:45SOC is auto-HCT:
Graham Collins, UK
 Debate: RR T cell NHL:
09:45-10:00Novel agents in R/R T cell lymphomas:
Christopher Fox, UK
10:00-10:15Allogeneic transplant in R/R T cell lymphomas:
Mehdi Hamadani, USA
10:15-10:30Roundtable discussion:
All session faculty
10:30-11:00Coffee Break
11:00-12:30Session 6:
Hodgkin’s lymhoma
 
 Moderators:
Stefano Luminari, Italy; Anna Sureda, Spain
11:00-11:20The role of radiotherapy in 2023:
Lena Specht, Denmark
11:20-11:40What is the role for response-adapted first-line treatment strategies?
Andrea Gallamini, France
11:40-12:00Is HDT and autoHCT still SOC in the era of novel therapies?
Ali Bazarbachi, Lebanon
12:00-12:20When do I consider allogeneic HCT in cHL previously treated with BV and CKI?
Miguel Perales, USA
12:20-12:30Roundtable discussion:
All session faculty
12:30-13:00Lunch Box Pick-up and Break
 COLYM Program Pause
 
14:45-15:15COLYM Plenary Lecture
 
14:45-15:05The latest in allogeneic CAR T:
Miguel Perales, USA
15:05-15:15Q&A
15:15-16:15Session 7:
Mantle cell lymphoma
 
 Moderators:
Christopher Fox, UK; Eva Domingo-Doménech, Spain
 
15:15-15:30Front line consolidation with high-dose therapy and auto-HCT and post-transplant R maintenance: Should this approach be adandoned?
Marek Trn?ný, Czech Republic
 Debate: Best therapy for RR MCL is:
 
15:30-15:45Cellular therapy:
Alejandro Martín García-Sancho, Spain
15:45-16:00BTKs:
Wojciech Jurczak, Poland
16:00-16:15Roundtable discussion:
All session faculty
16:15-16:30Coffee Break
 
16:30-17:00IACH Closing Plenary Lecture in Hall A

MPNCo&D Program

Friday, October 6, 2023
 Hall C
 
 Myeloproliferative Neoplasms (MPNCo&D)
09:15-10:45Session 1:
Polycythemia Vera in 2023 and beyond
 
 Moderators:
Naveen Pemmaraju, USA; Claire Harrison, UK & Ruben Mesa, USA
 Debate: Standard of care in PV
09:15-09:25Thrombosis/risk stratification in PV – aiming for a normal PBC:
Mary Frances McMullin, UK
 
09:25-09:35IFN in PV – with molecular monitoring:
Jean-Jacques Kiladjian, France
09:35-09:50PTG-300/Rusfertide: from bench to bedside – Hepcidin Mimetics in PV:
Ronald Hoffman, USA
 Debate: All PV patients should be treated
09:50-10:00Yes, including lower-risk:
Tiziano Barbui, Italy
10:00-10:10No, only higher risk:
Ruben Mesa, USA
10:10-10:25Should we still use HU for PV – can RUX go to the front line?
Claire Harrison, UK
10:25-10:45Roundtable discussion:
All session faculty
10:45-11:15Coffee Break
11:15-12:45Session 2:
Essential thrombocytosis – Can we do better?
 Moderators:
Claire Harrison, UK; Anna Godfrey, UK
11:15-11:35Higher risk ET: state-of-the-art management in 2023:
Claire Harrison, UK
11:35-11:50What is my approach to triple negative thrombocytosis?
Anna Godfrey, UK
11:50-12:10Should all patients with ET have aspirin?
Tiziano Barbui, Italy
12:00-12:30CALR: role of immunotherapy as future directions/novel approaches:
Bethan Psaila, UK
12:30-12:45Roundtable discussion:
All session faculty
12:45-13:00Lunch Box Pick-up and Break
 MPNCo&D Program Pause
 
14:45-16:15Session 3:
Myelofibrosis: current and novel approaches in a rapidly developing field
 Moderators:
Naveen Pemmaraju, USA; John Mascarenhas, USA
14:45-15:00Pre-fibrotic MF: a new entity with special considerations:
Paola Guglielmelli, Italy
15:00-15:15Early/lower risk MF: treatment options and approach:
Ruben Mesa, USA
15:15-15:30Int/higher risk MF: current treatment options in 2023:
John Mascarenhas, USA
15:30-15:45Current data for combinations for JAKi naïve patients:
Naveen Pemmaraju, USA
15:45-16:00Clinical and molecular factors, biomarkers of MPN progression: current and future:
Adam Mead, UK
16:00-16:15Anemia in MF: an emerging area for novel approaches:
Naveen Pemmaraju, USA
 
16:15-16:30Coffee Break
16:30-18:00Session 4:
Treatment of high-risk MF
 Moderators:
Florian Heidel, Germany; John Mascarenhas, USA
16:30-16:45How to define failure of JAKi:
Florian Heidel, Germany
16:45-17:00Current outcomes for transplantation in MF:
Maria Robin, France
 Debate: Future directions: Transplantation in MPN
17:00-17:10Transplant early before patients fail a JAKi:
Donal McLornan, UK
 
17:10-17:20Patients failing a JAKi can be salvaged without BMT:
John Mascarenhas, USA
17:20-17:35Novel agents in the clinic beyond JAKi:
Raajit Rampal, USA
17:35-18:00Roundtable discussion:
All session faculty
Saturday, October 7, 2023
 Hall C
 
 Myeloproliferative Neoplasms (MPNCo&D)
09:00-10:45Session 5:
AYA MPNs: pregnancy, thromboses and special considerations (ending at 10:45)
 
 Moderators:
Isabelle Plo, France; Ruben Mesa, USA
09:00-09:15New data for thrombosis in MPN:
Anna Falanga, Italy
09:15-09:30Gastro-oncology: splanchnic vein thrombosis a primer for haematologists:
David Patch, UK
09:30-09:45Cardio-oncology: primer on intersection of cardio-oncology and MPNs: arrythmias, clots, anticoagulation and cardiac considerations:
Michael Fradley, USA
09:45-10:00Pregnancy, fertility and hormone therapy: state-of-the-art considerations:
Susan Robinson, UK
10:00-10:15Young patients with MPNs: unique considerations in thromboses:
Jean-Christophe Ianotto, France
10:15-10:30Latest update on inheritability and MPN:
Isabelle Plo, France
10:30-10:45Roundtable discussion:
All session faculty
10:30-11:00Coffee Break
11:00-12:30Session 6:
Rare MPNs – Focus on emerging subtypes
 Moderators:
Deepti Radia, UK; Andreas Reiter, Germany
11:00-11:15Investigation and management of eosinophilia:
Andreas Reiter, Germany
11:15-11:30Aggressive SM: emerging therapy options:
Deepti Radia, UK
11:30-11:45Current management of CMML:
Eric Solary, France
11:45-12:00Investigation and management of congenital erythrocytosis:
Mary Frances McMullin, UK
12:00-12:30Roundtable discussion:
All session faculty
12:30-13:00Lunch Box Pick-up and Break
 MPNCo&D Program Pause
 
14:45-16:15Session 7:
Current and future considerations in MPNs and rare hematologic malignancies: building innovative, sustainable programs across the world
 Moderators:
Naveen Pemmaraju, USA; Ruben Mesa, USA
14:45-15:00What is patient advocacy?
Jonathan Mathias, UK
15:00-15:15Building MPN communities and the role of MPN advocates network:
Werner Zinkand, Germany
15:15-15:35Future directions in MPN: AI and MPN:
Daniel Royston, UK
15:35-15:55CHIP and MPNs: what have we learned from population studies in Denmark?
Hans Hasselbalch, Denmark
15:55-16:15Plenary lecture: MPNs and Targeting stem cells in MF: Past, Present and Future:
Ronald Hoffman, USA
16:15-16:30Coffee Break
16:30-17:00IACH Closing Plenary Lecture in Hall A



 

KEY DATES

Registrations Open
05 Sep, 2023
Registrations Open
Registrations Ends
07 Oct, 2023
Registration Ends
Event Start Date
05 Oct, 2023
Event Start Date
Event End Date
07 Oct, 2023
Event End Date

TARGET AUDIENCE

PhysicianNursingScientistsStudentsResidentsNursesHematologist

SPECIALITIES

Pathology - ClinicalHematologyHematopathologyHaematologyHematology Blood and Marrow TransplantHematology NurseHaematopathology

SUGGESTED HOTELS

CONFERENCE VENUE

New Cap Event Center
3 Quai de Grenelle
Explore more options
Hotels
Flights
Rides